|Bid||2.8300 x 3200|
|Ask||2.9400 x 3200|
|Day's range||2.7400 - 3.0100|
|52-week range||2.1500 - 13.6800|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.50|
Investing in stocks comes with the risk that the share price will fall. And unfortunately for 23andMe Holding Co...
In this podcast, Motley Fool contributor Brian Orelli interviews Anne Wojcicki, the CEO of 23andMe (NASDAQ: ME), about her company and why it's looking to tell you much more than the names of your long-lost relatives. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Anne Wojcicki: [MUSIC] When I think one of our legacies, hopefully, will be, is that 23andme has really proven that complicated information can go direct to a consumer, it does not have to have a one-to-one interaction with the physician.
The stock performance of 23andMe (NASDAQ: ME) has plunged since it went public last June. But, in this video clip from "The Rank" on Motley Fool Live, recorded on March 28, Fool.com contributors Matt Frankel and Travis Hoium discuss a few of the biotech company's promising business plans that could pay off in a big way over the next few years.